BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. Some articles will have been accepted based in part or entirely on reviews undertaken for other BMJ Group journals. These will be reproduced where possible.
GENERAL COMMENTS
This is descriptive study on rotavirus gastroenteritis (RVGE) in Greece in the years [2008] [2009] [2010] . Rotavirus vaccine was introduced in Greece in 2007 and used in private practice. In 2011 the vaccine was introduced in the National Immunization Programme, but only as an optional vaccine recommended for high risk groups and with 75 % reimbursement. The study years fall in between, and represent neither a pure vaccine free environment nor a post-vaccination environment with a known vaccine coverage. Therefore, the epidemiological and clinical observations have only a limited value. Moreover, Trimis et al (cited as ref. 10) have already described a small effect on RVGE of rotavirus vaccination in the private practice.
The strength of this study is that it covers 70% of the children population in Greece. Thus, the present study structure would be most suitable to describe the impact of large scale rotavirus vaccination on RVGE in Greece. However, the study comes too early to reach this goal, and no conclusions can be drawn on the basis of these results.
The study results suggest that the proportion of RV positive cases among all GE may be lower than before the launch of RV vaccines in Greece. The proportion of RV positive cases among outpatients was about 10% and among hospitalized patients about 24 %, but the figures cannot be reliably compared with prevaccination data. The authors are aware of this shortcoming. The age distribution of RVGE cases appears to be "normal", i.e. there is no apparent shift in age due to vaccinations. The epidemiological peak is in April, but it is not clear if this is shifted due to vaccinations.
In addition, the paper includes data on genotypes of RV and the clinical severity of RVGE. These parts are methodologically correct, but the results do not add anything that is not known already and are not of wider interest.
To estimate any vaccination effect it would be necessary to have some information on the coverage of RV vaccination during the study period. It is surprising that no information is provided.
The study design would also allow measurement/estimation of effectiveness of RV vaccine in a partially vaccinated community. To do this it would be necessary to collect information on vaccination status of RVGE patients. This crucial point is missing in the study protocol.
In summary, the study in its present form is inadequate to describe the effect of RV vaccination in Greece. Because of the good infrastructure, the study could serve as a baseline (or at least comparison) for the impact of RV vaccination in the Greek NIP, if the study will be continued in the current setting. If such assurance can be given, publishing this baseline would appear more justified.
VERSION 1 -AUTHOR RESPONSE
Reviewer #2: Prof. Timo Vesikari (University of Tampere) Overall: This is descriptive study on rotavirus gastroenteritis (RVGE) in Greece in the years 2008-2010. Rotavirus vaccine was introduced in Greece in 2007 and used in private practice. In 2011 the vaccine was introduced in the National Immunization Programme, but only as an optional vaccine recommended for high risk groups and with 75 % reimbursement. The study years fall in between, and represent neither a pure vaccine free environment nor a post-vaccination environment with a known vaccine coverage. Therefore, the epidemiological and clinical observations have only a limited value. Moreover, Trimis et al (cited as ref. 10) have already described a small effect on RVGE of rotavirus vaccination in the private practice. The strength of this study is that it covers 70% of the children population in Greece. Thus, the present study structure would be most suitable to describe the impact of large scale rotavirus vaccination on RVGE in Greece. However, the study comes too early to reach this goal, and no conclusions can be drawn on the basis of these results. The study results suggest that the proportion of RV positive cases among all GE may be lower than before the launch of RV vaccines in Greece. The proportion of RV positive cases among outpatients was about 10% and among hospitalized patients about 24 %, but the figures cannot be reliably compared with pre-vaccination data. The authors are aware of this shortcoming. The age distribution of RVGE cases appears to be "normal", i.e. there is no apparent shift in age due to vaccinations. The epidemiological peak is in April, but it is not clear if this is shifted due to vaccinations. In addition, the paper includes data on genotypes of RV and the clinical severity of RVGE. These parts are methodologically correct, but the results do not add anything that is not known already and are not of wider interest.
1. To estimate any vaccination effect it would be necessary to have some information on the coverage of RV vaccination during the study period. It is surprising that no information is provided. Response: Vaccination coverage reached post-availability of vaccines in Greece and before the introduction of RV vaccines in the national immunization programme was as follows: From 4.0% in 2006-07 the vaccine coverage increased to 25.0% in 2009-10, 25.0%. This information has been included in the manuscript.
2. The study design would also allow measurement/estimation of effectiveness of RV vaccine in a partially vaccinated community. To do this it would be necessary to collect information on vaccination
